Instrument Inactif

Communiqués Integrity Applications, Inc. Other OTC

Actions

IGAP

US45824Q1013

Recherche biotechnologique et médicale

Communiqués

08/07	Glucotrack Announces USPTO Notice of Allowance for Patent Application Covering Its Implantable CBGM Platform	AQ
26/05	Glucotrack to Highlight Implantable Continuous Blood Glucose Monitoring Technology at the American Diabetes Association’s 2026 Scientific Sessions	AQ
14/05	Glucotrack Reports First Quarter 2026 Financial Results and Recent Corporate Highlights	AQ
07/05	Glucotrack Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology	AQ
30/04	Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology	AQ
21/04	Glucotrack Announces Publication of Peer-Reviewed Study Supporting Long-Life Sensor Design for Implantable Continuous Blood Glucose Monitoring Technology	AQ
30/03	Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights	AQ
27/03	Glucotrack to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones	AQ
10/03	Glucotrack to Present at LSI USA ’26 Medtech Innovation Summit	AQ
29/01	Glucotrack Announces USPTO Approval for Issuance of Patents for Proprietary CBGM Platform	AQ
30/12	Glucotrack, Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor	AQ
13/11	Glucotrack Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights	AQ
03/11	Glucotrack, Inc. Encourages Shareholders to Vote	AQ
29/10/25	Glucotrack Appoints Neuromodulation and Painful Diabetic Neuropathy Expert, Usman Latif, MD, MBA, to Clinical Advisory Team	AQ
28/10/25	Glucotrack, Inc. Reminds Shareholders to Vote	AQ
11/09/25	Glucotrack to Participate in the Q3 Virtual Investor Summit	AQ
14/08/25	Glucotrack Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights	AQ
06/08/25	Glucotrack Expands Clinical Advisory Team Appointing David S. Hirsh, MD as Medical Director, Cardiology	AQ
31/07/25	Glucotrack to Exhibit at 2025 Association of Diabetes Care and Education Specialists Annual Meeting	AQ
08/07/25	Glucotrack Announces Repurchase of Series A Warrants	AQ
26/06/25	Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions	AQ
25/06/25	Glucotrack and OneTwo Analytics Present Positive Final Results of First-In-Human Study for Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions	AQ
12/06/25	Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements	AQ
10/06/25	Rebuilding Trust: How Glucotrack Is Establishing A New Standard In Diabetes Management	AQ
04/06/25	Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association’s 85th Scientific Sessions	AQ